Cambrian Biopharma

Oviva Therapeutics is a movement to improve women's experience of aging through biomedical research, development and advocacy.

Sensei Biotherapeutics is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. The company is dedicated to developing precision cancer therapeutics that target tumor-specific antigens, focusing on next-generation cancer immunotherapies. Utilizing its proprietary ImmunoPhage platform, Sensei Biotherapeutics creates immune-activating agents designed to engage both innate and adaptive immune systems. The company's TMAb (Tumor Microenvironment Activated Biologics) platform aims to develop selective therapeutics that either disable immunosuppressive signals or activate immunostimulatory signals within the tumor microenvironment. Sensei Biotherapeutics is advancing four investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which are in various stages of development. The company brings together expertise in biology, immunology, and oncology, supported by a seasoned management team and scientific advisors, to address unmet needs in cancer treatment.